MSB 3.21% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-101

  1. 1,228 Posts.
    lightbulb Created with Sketch. 695
    What a wonderful result for the world, for the company and for holders. The market hasn’t woken to this yet but when it does then KABOOM!!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.